

Nathalie Vernaz

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3052066/publications.pdf>

Version: 2024-02-01

44
papers

1,582
citations

471371

17
h-index

315616

38
g-index

44
all docs

44
docs citations

44
times ranked

1882
citing authors

#	ARTICLE	IF	CITATIONS
1	Bacteremia Detection in Second or Subsequent Blood Cultures Among Hospitalized Patients in a Tertiary Care Hospital. <i>JAMA Network Open</i> , 2022, 5, e228065.	2.8	1
2	Gender gap in medical research: a bibliometric study in Swiss university hospitals. <i>Scientometrics</i> , 2021, 126, 741-755.	1.6	12
3	Determination of antiretroviral drugs for buyersâ€™ club in Switzerland using capillary electrophoresis methods. <i>Electrophoresis</i> , 2021, 42, 708-718.	1.3	7
4	Accuracy of PubMed-based author lists of publications and use of author identifiers to address author name ambiguity: a cross-sectional study. <i>Scientometrics</i> , 2021, 126, 4121-4135.	1.6	5
5	SARS-CoV-2 testing strategy: A comparison of restricted and extended strategies in a Swiss outpatient cohort from the community and hospital employees. <i>PLoS ONE</i> , 2021, 16, e0250021.	1.1	3
6	Letermovir Primary Prophylaxis in High-Risk Hematopoietic Cell Transplant Recipients: A Matched Cohort Study. <i>Vaccines</i> , 2021, 9, 372.	2.1	22
7	NAFLD and MAFLD as emerging causes of HCC: A populational study. <i>JHEP Reports</i> , 2021, 3, 100231.	2.6	54
8	Clinical and Pharmacological Considerations for Concomitant Administration of Posaconazole and Isavuconazole with Letermovir. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, .	1.4	5
9	Development and validation of the OUTCoV score to predict the risk of hospitalisation among patients with SARS-CoV-2 infection in ambulatory settings: a prospective cohort study. <i>BMJ Open</i> , 2021, 11, e044242.	0.8	7
10	Hepatitis C prevalences in the psychiatric setting: Cost-effectiveness of scaling-up screening and direct-acting antiviral therapy. <i>JHEP Reports</i> , 2021, 3, 100279.	2.6	12
11	Clinical Considerations of Isavuconazole Administration in High-Risk Hematological Patients: A Single-Center 5-Year Experience. <i>Mycopathologia</i> , 2021, 186, 775-788.	1.3	5
12	Vulnerable patients forgo health care during the first wave of the Covid-19 pandemic. <i>Preventive Medicine</i> , 2021, 150, 106696.	1.6	27
13	Clinical considerations on posaconazole administration and therapeutic drug monitoring in allogeneic hematopoietic cell transplant recipients. <i>Medical Mycology</i> , 2021, 59, 701-711.	0.3	8
14	Impact of restricting procalcitonin measurements in a Swiss tertiary-care hospital on antibiotic use, clinical outcomes, and costs: An interrupted time-series analysis. <i>Infection Control and Hospital Epidemiology</i> , 2021, 42, 890-892.	1.0	0
15	Scientific publications in internal medicine and family medicine: a comparative cross-sectional study in Swiss university hospitals. <i>Family Practice</i> , 2020, 38, 299-305.	0.8	1
16	Hepatitis C virus screening of people with severe mental illness: a cost-effectiveness analysis. <i>Journal of Hepatology</i> , 2020, 73, S818-S819.	1.8	0
17	The Swiss Cheese Prescribing Model for Precision Medicine. <i>American Journal of Medicine</i> , 2020, 133, 1249-1251.	0.6	3
18	How to Develop and Implement a Computerized Decision Support System Integrated for Antimicrobial Stewardship? Experiences From Two Swiss Hospital Systems. <i>Frontiers in Digital Health</i> , 2020, 2, 583390.	1.5	6

#	ARTICLE	IF	CITATIONS
19	Early experimental COVID-19 therapies: associations with length of hospital stay, mortality and related costs. <i>Swiss Medical Weekly</i> , 2020, 150, w20446.	0.8	21
20	Access to unauthorized hepatitis C generics: Perception and knowledge of physicians, pharmacists, patients and non-healthcare professionals. <i>PLoS ONE</i> , 2019, 14, e0223649.	1.1	3
21	Cost-effectiveness of HLA-DQB1/HLA-B pharmacogenetic-guided treatment and blood monitoring in US patients taking clozapine. <i>Pharmacogenomics Journal</i> , 2019, 19, 211-218.	0.9	25
22	Title is missing!. , 2019, 14, e0223649.		0
23	Title is missing!. , 2019, 14, e0223649.		0
24	Title is missing!. , 2019, 14, e0223649.		0
25	Title is missing!. , 2019, 14, e0223649.		0
26	A buyersâ€™ club to improve access to hepatitis C treatment for vulnerable populations. <i>Swiss Medical Weekly</i> , 2018, 148, w14649.	0.8	6
27	Prioritization of Active Pharmaceutical Ingredients in Hospital Wastewater. <i>Handbook of Environmental Chemistry</i> , 2017, , 49-69.	0.2	1
28	Snapshot of the prescribing practice for the clopidogrel and esomeprazole coprescription and cost evaluation of the application guidelines. <i>Pharmacology Research and Perspectives</i> , 2016, 4, e00234.	1.1	3
29	Integrated stochastic modeling of pharmaceuticals in sewage networks. <i>Stochastic Environmental Research and Risk Assessment</i> , 2016, 30, 1087-1097.	1.9	13
30	Dynamics of active pharmaceutical ingredients loads in a Swiss university hospital wastewaters and prediction of the related environmental risk for the aquatic ecosystems. <i>Science of the Total Environment</i> , 2016, 547, 244-253.	3.9	68
31	Drug Pricing Evolution in Hepatitis C. <i>PLoS ONE</i> , 2016, 11, e0157098.	1.1	16
32	<i>Staphylococcus aureus</i> and methicillin resistance in Switzerland: regional differences and trends from 2004 to 2014. <i>Swiss Medical Weekly</i> , 2016, 146, w14339.	0.8	26
33	Prioritization methodology for the monitoring of active pharmaceutical ingredients in hospital effluents. <i>Journal of Environmental Management</i> , 2015, 160, 324-332.	3.8	40
34	Monitoring white blood cell count in adult patients with schizophrenia who are taking clozapine: a cost-effectiveness analysis. <i>Lancet Psychiatry</i> , 2014, 1, 55-62.	3.7	17
35	Patented Drug Extension Strategies on Healthcare Spending: A Cost-Evaluation Analysis. <i>PLoS Medicine</i> , 2013, 10, e1001460.	3.9	33
36	Temporal Variability of Antibiotics Fluxes in Wastewater and Contribution from Hospitals. <i>PLoS ONE</i> , 2013, 8, e53592.	1.1	46

#	ARTICLE	IF	CITATIONS
37	The impact of antibiotic use on the incidence and resistance pattern of extended-spectrum beta-lactamase-producing bacteria in primary and secondary healthcare settings. <i>British Journal of Clinical Pharmacology</i> , 2012, 74, 171-179.	1.1	87
38	Multihospital Outbreak of <i>Clostridium difficile</i> Ribotype 027 Infection: Epidemiology and Analysis of Control Measures. <i>Infection Control and Hospital Epidemiology</i> , 2011, 32, 210-219.	1.0	52
39	Modelling the impact of antibiotic use on antibiotic-resistant <i>Escherichia coli</i> using population-based data from a large hospital and its surrounding community. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 928-935.	1.3	77
40	Impact of Combined Low-Level Mupirocin and Genotypic Chlorhexidine Resistance on Persistent Methicillin-Resistant <i>Staphylococcus aureus</i> Carriage After Decolonization Therapy: A Case-control Study. <i>Clinical Infectious Diseases</i> , 2011, 52, 1422-1430.	2.9	163
41	Temporal effects of antibiotic use and <i>Clostridium difficile</i> infections. <i>Journal of Antimicrobial Chemotherapy</i> , 2009, 63, 1272-1275.	1.3	38
42	Quasiexperimental Study of the Effects of Antibiotic Use, Gastric Acid-Suppressive Agents, and Infection Control Practices on the Incidence of <i>Clostridium difficile</i> -Associated Diarrhea in Hospitalized Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 2082-2088.	1.4	46
43	Universal Screening for Methicillin-Resistant <i>Staphylococcus aureus</i> at Hospital Admission and Nosocomial Infection in Surgical Patients. <i>JAMA - Journal of the American Medical Association</i> , 2008, 299, 1149.	3.8	483
44	Temporal effects of antibiotic use and hand rub consumption on the incidence of MRSA and <i>Clostridium difficile</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2008, 62, 601-607.	1.3	140